2-hydroxyglutaric acid

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 1586 references associated with 2-hydroxyglutaric acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.

Here are additional resources we collected from PubChem and MeSH for 2-hydroxyglutaric acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-hydroxyglutaric acid

MeSH term MeSH ID Detail
Hyperoxaluria D006959 3 associated lipids
Metabolic Diseases D008659 12 associated lipids
Phenylketonurias D010661 7 associated lipids
Canavan Disease D017825 2 associated lipids
Tyrosinemias D020176 2 associated lipids
Total 5

PubChem Associated disorders and diseases

PubChem Biomolecular Interactions and Pathways

NCBI Entrez Crosslinks

All references with 2-hydroxyglutaric acid

Download all related citations
Per page 10 20 50 100 | Total 448
Authors Title Published Journal PubMed Link
Nadtochiy SM et al. Metabolomic profiling of the heart during acute ischemic preconditioning reveals a role for SIRT1 in rapid cardioprotective metabolic adaptation. 2015 J. Mol. Cell. Cardiol. pmid:26388263
Li L et al. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells. 2015 PLoS ONE pmid:26368816
Wu F et al. Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds. 2015 J. Med. Chem. pmid:26280302
Evans B and Griner E Registered report: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. 2015 Elife pmid:26231040
Intlekofer AM et al. Hypoxia Induces Production of L-2-Hydroxyglutarate. 2015 Cell Metab. pmid:26212717
Oldham WM et al. Hypoxia-Mediated Increases in L-2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress. 2015 Cell Metab. pmid:26212716
Tai H and Zhang Z A novel compound heterozygous mutation in a Chinese boy with L-2-hydroxyglutaric aciduria: a case study. 2015 BMC Neurol pmid:26208971
Fu X et al. 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. 2015 Cell Metab. pmid:26190651
Hwang VJ et al. The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate. 2015 Am. J. Physiol. Renal Physiol. pmid:26155843
Macaulay RJ Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas. 2015 Cancer Control pmid:26068765
Suijker J et al. The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo. 2015 Oncotarget pmid:26046462
Izquierdo-Garcia JL et al. IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism. 2015 Cancer Res. pmid:26045167
Pichumani K et al. Conditions for (13)C NMR detection of 2-hydroxyglutarate in tissue extracts from isocitrate dehydrogenase-mutated gliomas. 2015 Anal. Biochem. pmid:25908561
Lombardi G et al. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma. 2015 Oncologist pmid:25862748
Wen H et al. Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism. 2015 J. Neurochem. pmid:25251602
Suijker J et al. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. 2015 Oncotarget pmid:25895133
Worth AJ et al. Rotenone Stereospecifically Increases (S)-2-Hydroxyglutarate in SH-SY5Y Neuronal Cells. 2015 Chem. Res. Toxicol. pmid:25800467
Deng G et al. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. 2015 J. Biol. Chem. pmid:25391653
Natsumeda M et al. Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy. 2014 Acta Neuropathol Commun pmid:25376594
Chittaranjan S et al. Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity. 2014 Oncotarget pmid:25277207
Liu Z et al. Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity. 2014 J. Med. Chem. pmid:25271760
Shim EH et al. L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. 2014 Cancer Discov pmid:25182153
Saha SK et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. 2014 Nature pmid:25043045
Pope WB Intraoperative mass spectrometry of tumor metabolites. 2014 Proc. Natl. Acad. Sci. U.S.A. pmid:25028494
Reitman ZJ et al. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. 2014 J. Biol. Chem. pmid:24986863
Santagata S et al. Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. 2014 Proc. Natl. Acad. Sci. U.S.A. pmid:24982150
Kato Kaneko M et al. Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone. 2014 Cancer Sci. pmid:24898068
Fathi AT et al. Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. 2014 Oncologist pmid:24760710
Elhammali A et al. A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor. 2014 Cancer Discov pmid:24740997
Tarhonskaya H et al. Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases. 2014 Nat Commun pmid:24594748
Akbay EA et al. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. 2014 Genes Dev. pmid:24589777
Pusch S et al. D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma. 2014 Acta Neuropathol Commun pmid:24529257
Menendez JA et al. Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites. 2014 Cell Cycle pmid:24526120
Borger DR et al. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. 2014 Clin. Cancer Res. pmid:24478380
Işıkay S et al. A child with L-2 hydroxyglutaric aciduria presenting with dilated cardiomyopathy: coincidence or a new syndrome? 2014 Anadolu Kardiyol Derg pmid:24382499
Terunuma A et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. 2014 J. Clin. Invest. pmid:24316975
Gilbert MR et al. Autophagy and oxidative stress in gliomas with IDH1 mutations. 2014 Acta Neuropathol. pmid:24150401
Wang JH et al. Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. 2013 Proc. Natl. Acad. Sci. U.S.A. pmid:24082129
Lu C et al. Induction of sarcomas by mutant IDH2. 2013 Genes Dev. pmid:24065766
Chaumeil MM et al. Non-invasive in vivo assessment of IDH1 mutational status in glioma. 2013 Nat Commun pmid:24019001
McKenney AS and Levine RL Isocitrate dehydrogenase mutations in leukemia. 2013 J. Clin. Invest. pmid:23999441
Andronesi OC et al. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. 2013 J. Clin. Invest. pmid:23999439
Guilhamon P et al. Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2. 2013 Nat Commun pmid:23863747
Cairns RA and Mak TW Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. 2013 Cancer Discov pmid:23796461
DiNardo CD et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. 2013 Blood pmid:23641016
Losman JA and Kaelin WG What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. 2013 Genes Dev. pmid:23630074
Choi C et al. A comparative study of short- and long-TE ¹H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors. 2013 NMR Biomed pmid:23592268
Nota B et al. Deficiency in SLC25A1, encoding the mitochondrial citrate carrier, causes combined D-2- and L-2-hydroxyglutaric aciduria. 2013 Am. J. Hum. Genet. pmid:23561848
Wang F et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. 2013 Science pmid:23558173
Rohle D et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. 2013 Science pmid:23558169